FDA’s draft guidance for development of acute migraine drugs outlines an approach that includes a co-primary endpoint design including a “no pain” result, as opposed to just a reduction of pain, and another measure that would be based on effect on the most “bothersome symptom,” as prospectively identified by the patient.
The draft guidance notes that migraine is complex and that “effect on headache pain alone is not considered...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?